OBESITY has steadily emerged as a significant public health concern in the Philippines with increasing prevalence over the past decades. It used to be a concern among the high-income group but it has ...

Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE:NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects.

U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. The maker of blockbuster weight-loss ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk's total addressable market for GLP-1 drugs could grow significantly if this happens. The official WHO report that will include those recommendations is due out in August. The stock is ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

On Wednesday, BofA Securities revised its price target for Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) shares, lowering it to DKK850 from the previous DKK910. Despite the reduction, the firm ...

Such good fortune is affecting the companies which make them. Ozempic and Wegovy maker Novo Nordisk this week released its Q1 earnings, and it’s clear that GLP-1s are driving profits. Sales for the ...

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...